RECRUITING Phase 3 ClinicalTrials.gov

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

Sponsor: Takeda • ClinicalTrials.gov ID: NCT07250802

Registry updated: 2026-09-09

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it. The study will be done in 2 parts: Part A will include both children and teenagers, while part B will only include children. At first, only teenagers who meet the study rules can participate in this study. Children may only start to participate once enough information has been collected from other studies with zasocitinib. Participants in Part A will initially be assigned to receive either zasocitinib or placebo for the first 16 weeks of treatment, then all participants will receive zasocitinib through the end of the study. All participants in Part B will be assigned to receive treatment with zasocitinib throughout the study. Participants will be in the study for up to 4 years and 2 months (217 weeks), including up to 35 days for the screening period, 208 weeks of treatment (Part A and Part B) and a 4-week safety follow-up period. During the study, participants will visit their study site multiple times.

Interventions

Zasocitinib (Drug)
Zasocitinib.
Placebo (Drug)
Zasocitinib matching placebo.
Zasocitinib (Drug)
Zasocitinib.

Eligibility criteria

Inclusion Criteria: 1. Participant has a diagnosis of chronic plaque psoriasis for greater than or equal to (\>=) 6 months prior to the screening visit. 2. Participant has stable plaque psoriasis defined as no significant flare or change in morphology (as assessed by the investigator) in psoriasis for \>=6 months before screening. 3. Participant has moderate-to-severe plaque psoriasis as defined by a Psoriasis Area and Severity Index (PASI) score \>=12 and a Static Physician's Global Assessment (sPGA) score \>=3 at screening and Day 1. 4. Participant has plaque psoriasis covering \>=10 percent (%) of total body surface area (BSA) at screening and Day 1. 5. Participant must be a candidate for phototherapy or systemic therapy. 6. Inclusion Criteria for Part A Cohort 1: The participant is male or female and aged 12 to less than (\<) 18 years, inclusive. 7. Inclusion Criteria for Part A Cohort 2 and for Part B: The participant is male or female and aged 4 to \<12 years, inclusive. 8. Inclusion Criteria for Part A Cohort 1: The participant must weigh \>=40 kilograms (kg) at the time of screening. Exclusion Criteria: 1. Participant has evidence of nonplaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis). If a participant meets criteria for inclusion based on typical plaque psoriasis presentation, a limited amount of inverse psoriasis is not exclusionary. 2. Participant requires systemic treatment, other than nonsteroidal anti-inflammatory drugs (NSAIDs), during the trial period for an immune-related disease. 3. Participant has concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the trial assessments. 4. Participant has history of active TB infection, regardless of treatment status and has signs or symptoms of active TB or evidence of latent tuberculosis infection (LTBI). 5. Participant has active herpes virus infection, including herpes zoster or herpes simplex 1 and 2 or a history of serious herpetic infection. 6. Participant has a history of chronic or recurrent bacterial disease. 7. Participant has a history of opportunistic infections (for example, Pneumocystis jirovecii pneumonia, histoplasmosis, coccidiomycosis). 8. Participant has any clinically significant medical condition, evidence of an unstable clinical condition or vital signs/physical examination/laboratory/ECG abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of trial results. 9. Participant has any previous exposure to zasocitinib (also known as TAK-279 or NDI-034858) or other TYK2 inhibitors or participated in any trial that included a tyrosine kinase 2 (TYK2) inhibitor, unless participant has documentation of posttrial unblinding that confirms the participant did not receive a TYK2 inhibitor. 10. Participant is not up to date on all required vaccinations according to current immunization guidelines as noted by country-specific pediatric authorities. Other protocol-defined inclusion/exclusion criteria apply.

Conditions

Plaque Psoriasis

Locations

Exalt Clinical Research — Chula Vista, California, United States
First OC Dermatology Research Inc. — Fountain Valley, California, United States
Direct Helpers Medical Center — Hialeah, Florida, United States
Arlington Dermatology — Rolling Meadows, Illinois, United States
Apex Clinical Research Center, LLC — Canton, Ohio, United States
Wright State Physicians — Fairborn, Ohio, United States
Apex Clinical Research Center, LLC — Mayfield Heights, Ohio, United States
Medical University of South Carolina — Charleston, South Carolina, United States
UT Physicians Dermatology - Bellaire Station — Bellaire, Texas, United States
Texas Dermatology and Laser Specialists-San Antonio — San Antonio, Texas, United States
Medical College of Wisconsin — Milwaukee, Wisconsin, United States
Beijing Children Hospital, Capital Medical University — Beijing, Beijing Municipality, China
Dermatology Hospital of Southern Medical University — Guangzhou, Guangdong, China
Hunan Children's Hospital — Changsha, Hunan, China
Hangzhou First People's Hospital — Hangzhou, Zhejiang, China
Peking University Third Hospital — Beijing, China
Huashan Hospital Fudan University — Shanghai, China
Fachklinik Bad Bentheim — Bad Bentheim, Lower Saxony, Germany
Uniklinik Koln, Klinik fur Dermatologie und Venerologie — Cologne, North Rhine-Westphalia, Germany
University Hospital of Muenster — Münster, North Rhine-Westphalia, Germany
Universitätsklinikum Bonn — Bonn, Germany
Universitaetsmedizin der Johannes - Gutenberg Universitaet Mainz — Mainz, Germany
Presidio Ospedaliero Gaspare Rodolico — Catania, Sicily, Italy
Universita Degli Studi Di Padova — Padova, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Rome, Italy
Nagoya City University Hospital — Nagoya, Aichi-ken, Japan
Hospital of the University of Occupational and Environmental Health, Japan — Kitakyushu-shi, Fukuoka, Japan
Mie University Hospital — Tsu, Mie, Mie-ken, Japan
Nippon Life Hospital — Osaka, Osaka, Japan
Teikyo University Hospital — Itabashi-Ku, Tokyo, Japan
Cityclinic Przychodnia lekarsko psychologiczna Matusiak sp.p — Wroclaw, Lower Silesian Voivodeship, Poland
Luxderm Specjalistyczny Gabinet Dermatologiczny Dorota Krasowska — Lublin, Lublin Voivodeship, Poland
Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie — Rzeszów, Podkarpackie Voivodeship, Poland
Centrum Badan Klinicznych Pi-house Sp. Z O. O. — Gdansk, Pomeranian Voivodeship, Poland
"DERMED" Centrum Medyczne Sp. z o. o. — Lodz, Poland
Dermoklinika-Centrum Medyczne s.c — Lodz, Poland
Complejo Hospitalario Universitario de Santiago de Compostela — Santiago de Compostela, A Coruna, Spain
Hospital de La Santa Creu i Sant Pau - Dermatologia — Barcelona, Spain
Hospital Universitario 12 de Octubre — Madrid, Spain

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment